Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

774.61
+0.50000.06%
Post-market: 777.002.39+0.31%19:44 EDT
Volume:382.94K
Turnover:297.05M
Market Cap:79.75B
PE:19.16
High:779.98
Open:775.82
Low:771.80
Close:774.11
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.70
T/O Rate:0.39%
Dividend:3.64
Dividend Rate:0.47%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.51
PE(LYR):18.67

Loading ...

US FDA - Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin, Regeneron Join FDA Precheck Pilot

THOMSON REUTERS
·
Jun 30

Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program

MT Newswires Live
·
Jun 30

Lilly, Regeneron Selected for US Program to Review New Manufacturing Plants Faster

Reuters
·
Jun 30

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

TIPRANKS
·
Jun 30

Eli Lilly, Regeneron Among First Companies Selected for FDA Initiative to Speed Review of New Manufacturing Facilities - CNBC

THOMSON REUTERS
·
Jun 30

Healthcare Stocks Have Become a Haven for Investors Ditching Tech

Dow Jones
·
Jun 27

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 27

How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment

Simply Wall St.
·
Jun 27

Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call

Reuters
·
Jun 26

Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways

TIPRANKS
·
Jun 26

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion

Dow Jones
·
Jun 22

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Dow Jones
·
Jun 22

Regeneron says FDA accepts cemdisiran gMG filing for priority review

Reuters
·
Jun 22

Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

GlobeNewswire
·
Jun 22

AbbVie would gain an experimental eczema drug by buying biotech: report

Dow Jones
·
Jun 21